
    
      The E3810-J081-309 consisted of two arms: the long-term rabeprazole groups (participants from
      the rabeprazole 5 or 10 mg arm of the E3810-J081-308 study who entered the rabeprazole 5 mg
      or 10 mg arm of the E3810-J081-309 study) and the newly-initiated rabeprazole groups
      (participants from the teprenone 150 mg arm of the E3810-J081-308 study who entered the
      rabeprazole 5 mg or 10 mg arm of the E3810-J081-309 study).
    
  